Effect of indacaterol on cough and phlegm in chronic obstructive pulmonary disease patients: A meta-analysis of five randomized controlled trials

Journal of Korean Medical Science

Volumn 30, Issue 10, 2015, Pages 1453-1458

  Park, Jinkyeong ^a   Lee, Jung Su ^b   Rhee, Chinkook ^c   Oh, Yeon Mok ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Chronic Obstructive; Cough; Dyspnea; Indacaterol; Phlegm; Procaterol; Pulmonary Disease

Indexed keywords

ANTIINFECTIVE AGENT; BRONCHODILATING AGENT; INDACATEROL; INDAN DERIVATIVE; PLACEBO; QUINOLONE DERIVATIVE;

COUGH; DRUG EFFECTS; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SPUTUM; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; COUGH; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; PLACEBOS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SPUTUM; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84982728637     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2015.30.10.1453     Document Type: Article

References (24)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-8.
2. Lee JS, Rhee CK, Yoo KH, Lee JH, Yoon HI, Kim TH, Kim WJ, Lee J, Lim SY, Park TS, et al. Three-month treatment response and exacerbation in chronic obstructive pulmonary disease. J Korean Med Sci 2015; 30: 54-9.
3. Figarska SM, Boezen HM, Vonk JM. Dyspnea severity, changes in dyspnea status and mortality in the general population: the Vlagtwedde/Vlaardingen study. Eur J Epidemiol 2012; 27: 867-76.
4. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-40.
5. Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One 2014; 9: e85540.
6. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20: 799-805.
7. Calverley PM. Cough in chronic obstructive pulmonary disease: is it important and what are the effects of treatment? Cough 2013; 9: 17.
8. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T, Roche N; Initiatives Bronchopneumopathie Chronique Obstructive Scientific Committee. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975-82.
9. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011; 8: 340-5.
10. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med 2014; 14: 158.
11. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med 2013; 13: 26.
12. To Y, Kinoshita M, Lee SH, Hang LW, Ichinose M, Fukuchi Y, Kitawaki T, Okino N, Prasad N, Lawrence D, et al. Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population. Respir Med 2012; 106: 1715-21.
13. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, et al.; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-9.
14. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-62.
15. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-9.
16. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B; INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
17. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007; 28: 105-14.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
19. Leidy NK, Murray LT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD 2013; 10: 393-8.
20. Chung VC, Ma PH, Hui DS, Tam WW, Tang JL. Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8: e70784.
21. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7.
22. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999; 116: 1175-82.
23. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol 1992; 5: 257-63.
24. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells, in vitro. Pulm Pharmacol 1992; 5: 257-63.